U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

Development of a high-dose vaccine formulation for prevention of megalocytivirus infection in rock bream (Oplegnathus fasciatus)

Author:
Woo Ju Kwon, Jae Chan Choi, Suhee Hong, Young Chul Kim, Min Gyeong Jeong, Joon Gyu Min, Joon Bum Jeong, Kwang Il Kim, Hyun Do Jeong
Source:
Vaccine 2020 v.38 no.51 pp. 8107-8115
ISSN:
0264-410X
Subject:
Infectious spleen and kidney necrosis virus, Oplegnathus fasciatus, Pagrus major, adjuvants, aluminum hydroxide, antigens, bream, cell lines, dose response, mortality, squalene, water temperature
Abstract:
A formalin-inactivated red sea bream iridovirus (RSIV) vaccine was prepared using the culture supernatant of a persistently infected Pagrus major fin cell line (PI-PMF) with IVS-1 strain (RSIV subtype II Meglaocytivirus). Rock bream (Oplegnathus fasciatus) were injected with a high-dose, ultracentrifuged megalocytivirus vaccine (Ultra HSCMV, 7.0 × 10¹⁰ copies/mL), a high-dose supernatant of cultured megalocytivirus vaccine (HSCMV, 1.0 × 10¹⁰ copies/mL), a supernatant of cultured megalocytivirus vaccine (SCMV, 1.0 × 10⁹ copies/mL), and a low-dose of cultured megalocytivirus vaccine (LSCMV, 1.0 × 10⁸ copies/mL). The vaccine efficacies for the various vaccine formulations were determined done following injection challenge with IVS-1 (1.0 × 10⁴ copies/0.1 mL/fish), and the four different vaccines exhibited cumulative mortalities of 10.0 ± 0.0%, 48.3 ± 7.6%, 75.0 ± 5.0%, and 100.0 ± 0.0%, respectively. Additionally, the dose-dependent vaccine efficacy was also confirmed using two different cohabitation methods that included challenges G (general) and I (individual). When squalene + aluminum hydroxide (SqAl) was used as an adjuvant for the HSCMV or SCMV vaccine, cumulative mortalities of 30.0 ± 5.0% and 48.3 ± 7.6%, respectively, were obtained; moreover, these two adjuvants exhibited the highest efficacy in this study. The observed difference in survival post-challenge for the different vaccine concentrations was not reflected in the differences in neutralizing antibody titers. It was found that the water temperature during immune induction plays a less important a role than the water temperature during the challenge test, in which lowering the water temperature from 25 °C to 21 °C during a challenge improved the level of protection from cumulative mortalities from 35% to 10%. This study demonstrated that protection against mortality using inactivated vaccines against RSIVD in rock bream, which are known to be the most susceptible species to RSIV infection, is dependent upon antigen dose and temperature during the challenge.
Agid:
7176743